MARKET IS CLOSED
Loading latest tickers...

Market Indices

S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%

Sector Heatmap

Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%

GKOS — Glaukos Corporation

NYSE

Glaukos Corporation

CompareBack to Screener
$163.75
+0.58(+0.36%)
O
167.57
H
168.08
L
163.01
V
701.19K
⏱️ End-of-day dataAs of Oct 2, 2026

Chart

About GKOS

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

IndustrySURGICAL & MEDICAL INSTRUMENTS & APPARATUS
SectorNot available
IPO DateJun 25, 2015
Employees1,094
Stock ExchangeNYSE
Ticker SymbolGKOS

Key Financial Statistics

Market Cap$9.66B
P/E RatioN/A
Dividend YieldNone
EPSN/A
BetaN/A
52-Week Range$73.16 - $191.62
52-Week Avg Volume913.7K
VWAP$164.71
Transactions18,146
Total Recorded Bars2,835 days